Ostatnia aktualizacja :
29/10/2024
Antybiotyk   Netilmicin sulfate  
Injekcje
Aerozol
Trwałość roztworów Trwałość w mieszaninie Czynnik wpływający na trwałość Zgodność Sposób podania Bibliografia pdf
   Struktura chemiczna  

Nazwa handlowa   Nazwa handlowa     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Bactob Indie
Beltob Indie
Bramicil Włochy
Brulamycin Węgry
Eltol Indie
Fytobra Indie
Gernebcin Niemcy
Komitub Indie
Nebcin Arabia Saudyjska, Australia, Egipt, Grecja, nowa Zelandia, Wielka Brytania, Zjednoczone Emiraty Arabskie
Nebcina Dania, Maroko, Norwegia, Szwecja
Nebcine Maroko
Nebicina Włochy
Netilyn Finlandia, Szwecja
Netromicina Portugalia
Netromicine Francja
Netromycine Grecja, Polska, rosyjski, Turcja
Nettacin Włochy
Obracin Belgia, Holandia, Luksemburg, Szwajcaria
Tobra Niemcy
Tobra Alex Egipt
Tobra Day nowa Zelandia
Tobra Gobens Hiszpania
Tobracin Egipt
Tobradistin Hiszpania
Tobramicina Hiszpania, Portugalia, Wenezuela, Włochy
Tobramina Brazylia
Tobramycin Arabia Saudyjska, Australia, Irlandia, Kanada, Niemcy, Norwegia, Stany Zjednoczone Ameryki, Wielka Brytania
Tobramycine Belgia, Holandia, Kanada, Luksemburg
Tobrasix Austria
Tobrazid Niemcy
Tomycin Finlandia
Zetamicin Włochy
Bibliografia   Injekcje   Bibliografia : Netilmicin sulfate  
typ publikacja
3 Czasopismo Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59 Czasopismo Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
84 Czasopismo Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 Czasopismo Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 Czasopismo Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 Czasopismo Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Czasopismo Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
289 Czasopismo Jim LK.
Physical and chemical compatibility of intravenous ciprofloxacin with other drugs.
Ann Pharmacotherapy 1993 ; 27: 704-707.
299 Czasopismo Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Czasopismo Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.
Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Czasopismo Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
335 Czasopismo Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
367 Czasopismo Thompson DF, Allen LV, Desai SR, Rao PS.
Compatibility of furosemide with aminoglycoside admixtures.
Am J Hosp Pharm 1985 ; 42: 116-119.
421 Czasopismo Foley PT, Bosso JA, Bair JN, Townsend RJ.
Compatibility of clindamycin phosphate with cefotaxim sodium or netilmicin sulfate in small-volume admixtures.
Am J Hosp Pharm 1985 ; 42: 839-843.
492 Czasopismo Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
905 Czasopismo Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
921 Czasopismo Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
958 Czasopismo Vervloet E, Lammers J, Tan LSL, Van Mourik CH, Rots M.
Netilmicin sulfate stability in combinaison with metronidazole or ranitidine hydrochloride in NaCl 0.9% infusion.
Ann Pharmacotherapy 1990 ; 24: 440-442.
999 Czasopismo Watson D.
Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution.
JPEN 1985 ; 9: 220-224.
1022 Czasopismo Hutchinson SMW.
Heparin and aminoglycosides instability.
Drug Intell Clin Pharm 1986 ; 20: 886.
1035 Czasopismo Bisaillon S, Sarrazin R.
Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion.
J Parenter Sci Technol 1983 ; 37: 129-132.
1200 Czasopismo Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742.
1236 Czasopismo Kuhn RJ, Nahata MC.
Stability of netilmicin sulfate in admixtures with calcium gluconate and aminophylline.
Am J Hosp Pharm 1986 ; 43: 1241-1242.
1410 Czasopismo Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Czasopismo Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.
Compatibility of medications with 3-in-1 parenteral nutrition admixtures.
JPEN 1999 ; 23: 67-74.
1423 Czasopismo Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1754 Czasopismo Trissel LA, Gilbert DL, Wolkin AC.
Compatibility of docetaxel with selected drugs during simulated Y-site administration.
Int J Pharm Compound 1999 ; 3: 241-244.
1925 Czasopismo Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1929 Czasopismo Rigge DC, Jones MF.
Shelf lives of aseptically prepared medicines - stability of netilmicin injection in polypropylene syringes.
J Pharm Biomed Anal 2004 ; 35: 1251-1256.
2296 Laboratorium Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3522 Laboratorium Flucloxacillin - Summary of Product Characteristics.
Actavis 2013
3523 Laboratorium Ceftriaxone (Rocephin®) - Summary of Product Characteristics.
Roche 2018
3526 Laboratorium Clindamycin (Dalacin®) - Summary of Product Characteristics
Pharmacia 2010
3527 Laboratorium Amoxicillin (Amoxil®) – Summary of Product Characteristics
Glaxo Smith Kline 2018
3540 Laboratorium Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3543 Laboratorium Ceftazidime – Summary of Product Characteristics
Wockhardt 2013
3544 Laboratorium Cefoperazone (Cefobid®) - Summary of Product Characteristics
Pfizer 2006
3545 Laboratorium Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit
Mylan SAS 2009
3546 Laboratorium Cefamandole Flavelab - Résumé des caractéristiques du produit
Panpharma SA 2007
3548 Laboratorium Cefepime (Maxipime®) - Summary of Product caracteristics.
Bristol Myers Squibb 2007
3578 Laboratorium Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011
3586 Laboratorium Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit
Actavis France 2010
3587 Laboratorium Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics
GlaxoSmithKline 2014
3594 Laboratorium Metronidazole (Flagyl®) - Summary of Product Characteristics
Zentiva 2013
3644 Laboratorium Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3656 Laboratorium Teicoplanine (Targocid®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2014
3674 Laboratorium Erythromycin lactobionate - Summary of Product Characteristics
PanPharma 2016
3687 Laboratorium Cefuroxime sodium - Summary of Product Characteristics
Stravencon 2013
3883 Laboratorium Ceftazidime - Résumé des caractéristiques du produit
Arrow 2016

  Mentions Légales